NasdaqCM:CMPXBiotechs
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance
Clinical milestones and earnings set the context for Compass Therapeutics stock
Compass Therapeutics (CMPX) has been in focus after reaching the planned survival event threshold in its Phase 2/3 COMPANION-002 trial for biliary tract cancer, along with FDA clearance for its CTX-10726 investigational program.
These developments come as the company reported a full year 2025 net loss of US$66.49 million and a fourth quarter net loss of US$15.72 million, figures that help frame current...